The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus
Open accessAbstract
In type-2 diabetes, the overall incretin effect is reduced. The present investigation was designed to compare insulinotropic actions of exogenous incretin hormones (gastric inhibitory peptide [GIP] and glucagon-like peptide 1 [GLP-1] [7-36 amide]) in nine type-2 diabetic patients (fasting plasma glucose 7.8 mmol/liter; hemoglobin A1c 6.3 +/- 0.6%) and in nine age- and weight-matched normal subjects. Synthetic human GIP (0.8 and 2.4 pmol/kg.min over 1 h each), GLP-1 [7-36 amide] (0.4 and 1.2 pmol/kg.min over 1 h each), and placebo were administered under hyperglycemic clamp conditions (8.75 mmol/liter) in separate experiments. Plasma GIP and GLP-1 [7-36 amide] concentrations (radioimmunoassay) were comparable to those after oral glucose with the low, and clearly supraphysiological with the high infusion rates. Both GIP and GLP-1 [7-36 amide] dose-dependently augmented insulin secretion (insulin, C-peptide) in both groups (P < 0.05). With GIP, the maximum effect in type-2 diabetic patients was significantly lower (by 54%; P < 0.05) than in normal subjects. With GLP-1 [7-36 amide] type-2 diabetic patients reached 71% of the increments in C-peptide of normal subjects (difference not significant). Glucagon was lowered during hyperglycemic clamps in normal subjects, but not in type-2 diabetic patients, and further by GLP-1 [7-36 amide] in both groups (P < 0.05), but not by GIP. In conclusion, in mild type-2 diabetes, GLP-1 [7-36 amide], in contrast to GIP, retains much of its insulinotropic activity. It also lowers glucagon concentrations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In individuals with T2DM, there is a decrease in the incretin effect which primarily attributed to the diminished effects of gastric inhibitory polypeptide (GIP).9”
From GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review (2024) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Among the two incretin hormones, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), the latter has been established as having therapeutic potential for reducing elevated plasma glucose (1, 2) and body weight (3), while the former has been unable to either stimulate insulin secretion (1) or lower plasma glucose effectively in type 2 diabetes (T2D) (4).”
From The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications (2026) · cites this paper as [1]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Despite the slight differences based on the subject cohort and the duration of treatment, this magnitude of weight loss was largely consistent with the SURPASS trials132-140.”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [137]
Experimental — accuracy not yet measuredIn the citing paper
“which is not observed in the set of T2D where the endocrine pancreas ceases responsiveness to GIP but remains responsive to GLP-1, explaining the reduced/absent incretin effect of GIP in T2D [22,23].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [23]
In the citing paper
“However, GIP action is lost in T2D and even infusions of GIP that result in supraphysiological concentrations fail to elicit a significant insulin secretory response in T2D patients.160”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [160]
In the citing paper
“in type 2 diabetes, a markedly attenuated insulinotropic action of GIP (66) and, in some cases, attenuated secretion of GLP-1 (67), contribute to an impairment of postprandial insulin secretion, so that the latter is insufficient to maintain euglycaemia.”
From Gut mechanisms linking intestinal sweet sensing to glycemic control (2018) · cites this paper as [66]
In the citing paper
“In the setting of GIP/GLP-1 receptor agonist (dual agonism), GLP-1 quells the potential glucagon-stimulatory effects of GIP (64) and also (re)sensitizes beta cells to GIP's incretin effects (57), all while potentially enhancing GIP's beneficial effects on weight regulation mechanisms.”
From New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics (2023) · cites this paper as [57]
In the citing paper
“It remained in the shadow of GLP-1, partly because GIP-stimulated insulin secretion is significantly blunted in individuals with T2D (56); notably, responsiveness can be restored by mitigating hyperglycemia (57).”
From New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics (2023) · cites this paper as [57]
In the citing paper
“GIP has been found to stimulate glucagon secretion, particularly at lower glucose values [14], whereas GLP-1 suppresses glucagon release and, consequently, reduces hepatic glucose production [15].”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [15]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glucose clamp technique: a method for quantifying insulin secretion and resistance.
DeFronzo, R. A., Tobin, J. D., & Andres, R. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.237.3.e214 · Cited by 7,425
The Triumvirate: β-Cell, Muscle, Liver: A Collusion Responsible for NIDDM
DeFronzo, R. A. (1988) · Diabetes · doi:10.2337/diab.37.6.667 · Cited by 2,456
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
Reduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307
Self-citationPlasma Insulin Responses to Oral and Intravenous Glucose: Studies in Normal and Diabetic Subjects*
Perley, M. J., & Kipnis, D. M. (1967) · Journal of Clinical Investigation · doi:10.1172/jci105685 · Cited by 917
Mojsov, S., Weir, G. C., & Habener, J. F. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112855 · Cited by 889
NAUCK, M. A., HOMBERGER, E., SIEGEL, E. G., ALLEN, R. C., EATON, R. P., EBERT, R., & CREUTZFELDT, W. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-63-2-492 · Cited by 874
Self-citationGutniak, M., Ørkov, C., Holst, J. J., Ahrén, B., & Efendić, S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262003 · Cited by 868
Self-citationSTIMULATION OF INSULIN SECRETION BY GASTRIC INHIBITORY POLYPEPTIDE IN MAN. 1
Dupre, J., Ross, S. A., Watson, D., & Brown, J. C. (1973) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-37-5-826 · Cited by 860
Creutzfeldt, W. (1979) · Diabetologia · doi:10.1007/bf01225454 · Cited by 731
Self-citation
Research works printed but not linked: 1
- [45]45. Creutzfeldt, W., and U. R. Folsch. 1983. Delaying Absorption as a Thera- peutic Principle in Metabolic Disease. Georg-Thieme-Verlag, Stuttgart.
Cited by
Sorted by citations
Items 701–800 of 1,003
Vasu, S., Moffett, R. C., McClenaghan, N. H., & Flatt, P. R. (2015) · Experimental Cell Research · doi:10.1016/j.yexcr.2015.05.022 · Cited by 37
Gut: A key player in the pathogenesis of type 2 diabetes?
Muscogiuri, G., Balercia, G., Barrea, L., Cignarelli, A., Giorgino, F., Holst, J. J., Laudisio, D., Orio, F., Tirabassi, G., & Colao, A. (2016) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2016.1252712 · Cited by 37
Self-citationHeo, C. U., & Choi, C. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8030393 · Cited by 40
Gabe, M. B. N., van der Velden, W. J. C., Smit, F. X., Gasbjerg, L. S., & ROSENKILDE, M. M. (2019) · Peptides · doi:10.1016/j.peptides.2019.170224 · Cited by 38
Bolli, G. B., & Owens, D. R. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12253 · Cited by 37
Miki, H., Namba, M., Nishimura, T., Mineo, I., Matsumura, T., Miyagawa, J., Nakajima, H., Kuwajima, M., Hanafusa, T., & Matsuzawa, Y. (1996) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/0167-4889(96)00032-8 · Cited by 37
Incretin hormone expression in the gut of diabetic mice and rats
Berghöfer, P., Peterson, R. G., Schneider, K., Fehmann, H. C., & Göke, B. (1997) · Metabolism · doi:10.1016/s0026-0495(97)90251-1 · Cited by 37
Evaluation of beta-cell secretory capacity using glucagon-like peptide 1.
Vilsbøll, T., Toft-Nielsen, M.-B., Krarup, T., Madsbad, S., Dinesen, B., & Holst, J. J. (2000) · Diabetes Care · doi:10.2337/diacare.23.6.807 · Cited by 37
Self-citationByrd, R. A., Sorden, S. D., Ryan, T., Pienkowski, T., LaRock, R., Quander, R., Wijsman, J. A., Smith, H. W., Blackbourne, J. L., Rosol, T. J., et al. (2015) · Endocrinology · doi:10.1210/en.2014-1722 · Cited by 36
Incretin drugs as modulators of atherosclerosis
Gallego-Colon, E., Wojakowski, W., & Francuz, T. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.09.011 · Cited by 35
Pharmacological management of type 2 diabetes: the potential of incretin‐based therapies
Charbonnel, B. H., & Cariou, B. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01317.x · Cited by 37
Gut Hormone Regulation and Secretion via FFA1 and FFA4
Gribble, F. M., Diakogiannaki, E., & Reimann, F. M. (2016) · Handbook of experimental pharmacology · doi:10.1007/164_2016_46 · Cited by 33
Interleukin-17 acts in the hypothalamus reducing food intake
Nogueira, G. A. S., Solon, C., Carraro, R. S., Engel, D. F., Ramalho, A. F. S., Sidarta-Oliveira, D., Gaspar, R. S., Bombassaro, B., Vasques, A. C. J., Geloneze, B., et al. (2019) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2019.12.012 · Cited by 41
New Therapeutic Strategies for the Treatment of Type 2 Diabetes Mellitus Based on Incretins
Gallwitz, B. (2005) · The Review of Diabetic Studies · doi:10.1900/rds.2005.2.61 · Cited by 36
Harada, N., Hamasaki, A., Yamane, S., Muraoka, A., Joo, E., Fujita, K., & Inagaki, N. (2010) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2010.00078.x · Cited by 36
Eriksen, M., Jensen, D. H., Tribler, S., Holst, J. J., Madsbad, S., & Krarup, T. (2015) · Diabetologia · doi:10.1007/s00125-015-3522-y · Cited by 35
Self-citationGault, V. A., Kerr, B. D., Irwin, N., & Flatt, P. R. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.03.011 · Cited by 36
On the role of the incretin hormones GIP and GLP-1 in the pathogenesis of Type 2 diabetes mellitus.
Vilsbøll, T. (2004) · PubMed · Cited by 36
Anvari, M., Paterson, C. A., Daniel, E. E., & McDonald, T. J. (1998) · Digestive Diseases and Sciences · doi:10.1023/a:1018863716749 · Cited by 36
Hargrove, D. M., Nardone, N. A., Persson, L. M., Parker, J. C., & Stevenson, R. W. (1995) · Metabolism · doi:10.1016/0026-0495(95)90021-7 · Cited by 36
Molecular Basis of Pancreas Development and Function
Habener, J. F., & Hussain, M. A. (2001) · Endocrine updates · doi:10.1007/978-1-4615-1669-9 · Cited by 36
Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management
Son, J. W., & Lim, S. (2024) · Endocrinology and Metabolism · doi:10.3803/enm.2024.1940 · Cited by 33
Cracking the combination: Gut hormones for the treatment of obesity and diabetes
Alexiadou, K., Anyiam, O., & Tan, T. (2019) · Journal of Neuroendocrinology · doi:10.1111/jne.12664 · Cited by 34
GIP’s involvement in the pathophysiology of type 2 diabetes
Christensen, M. B., Gasbjerg, L. S., Heimbürger, S. M., Stensen, S., Vilsbøll, T., & Knop, F. K. (2020) · Peptides · doi:10.1016/j.peptides.2019.170178 · Cited by 35
Guo, X. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1103214 · Cited by 39
Type 2 Diabetes Mellitus: A Possible Surgically Reversible Intestinal Dysfunction
Sala, P. C., Torrinhas, R. S., Heymsfield, S. B., & Waitzberg, D. L. (2011) · Obesity Surgery · doi:10.1007/s11695-011-0563-2 · Cited by 36
Parry, S. A., Smith, J. R., Corbett, T. R. B., Woods, R. M., & Hulston, C. J. (2017) · British Journal Of Nutrition · doi:10.1017/s0007114516004475 · Cited by 35
Harnessing the Therapeutic Potential of Glucagon-Like Peptide-1
Baggio, L. L., & Drucker, D. J. (2002) · Treatments in Endocrinology · doi:10.2165/00024677-200201020-00005 · Cited by 35
Similar incretin secretion in obese and non-obese Japanese subjects with type 2 diabetes
Kozawa, J., Okita, K., Imagawa, A., Iwahashi, H., Holst, J. J., Yamagata, K., & Shimomura, I. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.01.134 · Cited by 35
Self-citation“The next big thing” in diabetes: clinical progress on DPP‐IV inhibitors
von Geldern, T. W., & Trevillyan, J. M. (2006) · Drug Development Research · doi:10.1002/ddr.20138 · Cited by 35
Wheeler, M. B., Gelling, R. W., Hinke, S. A., Tu, B., Pederson, R. A., Lynn, F. C., Ehses, J. A., & McIntosh, C. H. S. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.35.24593 · Cited by 35
Genetic disruption of the Gipr in Apoe−/− mice promotes atherosclerosis
Pujadas, G., Baggio, L. L., Kaur, K. D., McLean, B. A., Cao, X., & Drucker, D. J. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101586 · Cited by 34
Stimulating intestinal GIP release reduces food intake and body weight in mice
Lewis, J. E., Nuzzaci, D., James-Okoro, P.-P., Montaner, M., O’Flaherty, E. A. A., Darwish, T., Hayashi, M., Liberles, S. D., Hornigold, D. C., Naylor, J., et al. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.101945 · Cited by 37
Ahn, C. H., Oh, T. J., Kwak, S. H., & Cho, Y. M. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13081 · Cited by 33
Hasib, A., Ng, M. T., Khan, D., Gault, V. A., Flatt, P. R., & Irwin, N. (2018) · Peptides · doi:10.1016/j.peptides.2017.10.015 · Cited by 34
Kaneko, S. (2022) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2022.18.1.10 · Cited by 35
Dotson, C. D., Vigues, S., Steinle, N., & Munger, S. D. (2010) · PubMed · Cited by 34
The contribution of incretin hormones to the pathogenesis of type 2 diabetes
Meier, J. J. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.03.007 · Cited by 34
Triplitt, C. L., McGill, J. B., Porte, D., & Conner, C. S. (2007) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2007.13.9-c.1 · Cited by 35
MacNeil, S., Rebry, R. M., Tetlow, I. J., Emes, M. J., McKeown, B., & Graham, T. E. (2013) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/apnm-2013-0023 · Cited by 37
Montrose‐Rafizadeh, C., Wang, Y., Janczewski, A. M., Henderson, T. E., & Egan, J. M. (1997) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(97)00079-8 · Cited by 34
Novel GLP-1-based Medications for Type 2 Diabetes and Obesity
Son, J. W., le Roux, C. W., Blüher, M., Nauck, M. A., & Lim, S. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnaf036 · Cited by 40
Self-citationSeino, Y., Hiroi, S., Hirayama, M., & Kaku, K. (2012) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2012.00226.x · Cited by 33
Ma, J., Checklin, H. L., Wishart, J. M., Stevens, J. E., Jones, K. L., Horowitz, M., Meyer, J. H., & Rayner, C. K. (2013) · Diabetologia · doi:10.1007/s00125-013-2876-2 · Cited by 34
Hasib, A., Ng, M. T., Gault, V. A., Khan, D., Parthsarathy, V., Flatt, P. R., & Irwin, N. (2016) · Diabetologia · doi:10.1007/s00125-016-4186-y · Cited by 33
Recent advances of GIP and future horizons
Holst, J. J., & ROSENKILDE, M. M. (2019) · Peptides · doi:10.1016/j.peptides.2019.170230 · Cited by 33
Self-citationWang, Y., Wang, A., Alkhalidy, H., Luo, J., Moomaw, E., Neilson, A. P., & Liu, D. (2020) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201900978 · Cited by 39
Can dipeptidyl peptidase-4 inhibitors treat cognitive disorders?
Cheng, Q., Cheng, J., Cordato, D. J., & Gao, J. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107559 · Cited by 34
Characterisation of the biological activity of xenin-25 degradation fragment peptides
Martin, C. M., Parthsarathy, V., Pathak, V., Gault, V. A., Flatt, P. R., & Irwin, N. (2014) · Journal of Endocrinology · doi:10.1530/joe-13-0617 · Cited by 33
Type 2 Diabetes Mellitus and Glucagon Like Peptide-1 Receptor Signalling
Thompson, K. A. (2013) · Clinical and Experimental Pharmacology · doi:10.4172/2161-1459.1000138 · Cited by 36
Fujimoto, W., Miki, T., Ogura, T., Zhang, M., Seino, Y., Satin, L. S., Nakaya, H., & Seino, S. (2009) · Diabetologia · doi:10.1007/s00125-009-1306-y · Cited by 32
Heimbürger, S. M. N., Hoe, B., Nielsen, C. N., Bergmann, N. C., Skov‐Jeppesen, K., Hartmann, B., Holst, J. J., Dela, F., Overgaard, A. J., Størling, J., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac542 · Cited by 32
Self-citationPaschetta, E., Hvalryg, M., & Musso, G. (2011) · Obesity Reviews · doi:10.1111/j.1467-789x.2011.00897.x · Cited by 34
Tatarkiewicz, K., Hargrove, D. M., Jodka, C. M., Gedulin, B. R., Smith, P. A., Hoyt, J. A., Lwin, A. N., Collins, L., Мамедова, Л. Т., Levy, O. E., et al. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12181 · Cited by 33
Martin, C. M., Parthsarathy, V., Hasib, A., Ng, M. T., McClean, S., Flatt, P. R., Gault, V. A., & Irwin, N. (2016) · PLoS ONE · doi:10.1371/journal.pone.0152818 · Cited by 32
Skytte, M. J., Samkani, A., Astrup, A. V., Frystyk, J., Rehfeld, J. F., Holst, J. J., Madsbad, S., Burling, K., Fenger, M., Thomsen, M. N., et al. (2020) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00165.2020 · Cited by 43
Self-citationPinkney, J. H. (2010) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s7313 · Cited by 31
Burcelin, R., ROLLAND, E., Dolci, W., GERMAIN, S., CARREL, V., & Thorens, B. (1999) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1999.tb08510.x · Cited by 34
Galanin is a potent inhibitor of glucagon-like peptide-1 secretion from rat ileum
Herrmann-Rinke, C., Hörsch, D., McGregor, G. P., & Göke, B. (1996) · Peptides · doi:10.1016/0196-9781(96)00072-1 · Cited by 32
Metabolism of GIP and the contribution of GIP to the glucose-lowering properties of DPP-4 inhibitors
Deacon, C. F. (2020) · Peptides · doi:10.1016/j.peptides.2019.170196 · Cited by 31
Mechanisms and clinical applications of incretin therapies for diabetes and chronic kidney disease
Alicic, R. Z., Neumiller, J. J., & Tuttle, K. R. (2023) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000894 · Cited by 33
Ismail, S., Dubois-Vedrenne, I., Laval, M., Tikhonova, I. G., D’Angelo, R., Sanchez, C., Clerc, P., Ghérardi, M.-J., Gigoux, V., Magnan, R., et al. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.07.001 · Cited by 31
Renner, S., Blutke, A., Streckel, E., Wanke, R., & Wolf, E. (2015) · The Journal of Pathology · doi:10.1002/path.4655 · Cited by 30
Riedel, M. J., Gaddy, D. F., Asadi, A., Robbins, P. D., & Kieffer, T. J. (2009) · Gene Therapy · doi:10.1038/gt.2009.143 · Cited by 31
Comparison of liraglutide versus other incretin‐related anti‐hyperglycaemic agents
Blonde, L., & Montanya, E. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01575.x · Cited by 31
Complementing Insulin Therapy to Achieve Glycemic Control
Barnett, A. H. (2013) · Advances in Therapy · doi:10.1007/s12325-013-0039-y · Cited by 33
Tian, L., Ning, H., Shao, W., Song, Z., Badakhshi, Y., Ling, W., Yang, B. B., Brubaker, P. L., & Jin, T. (2020) · Journal of Nutrition · doi:10.1093/jn/nxaa140 · Cited by 31
Block, C. E. M. D., Dirinck, E. L., Verhaegen, A. A., & Gaal, L. F. V. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14640 · Cited by 33
The Role of GLP-1 in the Regulation of Islet Cell Mass
Bulotta, A., Farilla, L., Hui, H., & Perfetti, R. (2004) · Cell Biochemistry and Biophysics · doi:10.1385/cbb:40:3:65 · Cited by 34
Using the lymphatics to study nutrient absorption and the secretion of gastrointestinal hormones
Kohan, A. B., Yoder, S. M., & Tso, P. (2011) · Physiology & Behavior · doi:10.1016/j.physbeh.2011.04.056 · Cited by 32
Tian, J., Liu, Y., Liu, Y., Chen, K., & Lyu, S. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/9080869 · Cited by 32
Glucagon-like peptide 1 (GLP-1) and metabolic diseases
Rotella, C. M., Pala, L., & Mannucci, E. (2005) · Journal of Endocrinological Investigation · doi:10.1007/bf03347560 · Cited by 31
Manhart, S., Hinke, S. A., McIntosh, C. H. S., Pederson, R. A., & Demuth, H. (2003) · Biochemistry · doi:10.1021/bi026868e · Cited by 31
Distribution and Stimulus Secretion Coupling of Enteroendocrine Cells along the Intestinal Tract
Adriaenssens, A. E., Reimann, F. M., & Gribble, F. M. (2018) · Comprehensive physiology · doi:10.1002/cphy.c170047 · Cited by 39
Jonik, S., Marchel, M., Grabowski, M., Opolski, G., & Mazurek, T. (2022) · Biology · doi:10.3390/biology11020288 · Cited by 33
The Role of Incretin Therapy at Different Stages of Diabetes
Cernea, S. (2011) · The Review of Diabetic Studies · doi:10.1900/rds.2011.8.323 · Cited by 30
Vora, J. P., Bain, S. C., Damcı, T., Dzida, G. J., Hollander, P. A., Meneghini, L., & Ross, S. (2012) · Diabetes & Metabolism · doi:10.1016/j.diabet.2012.08.002 · Cited by 31
Chronic high-fat feeding increases GIP and GLP-1 secretion without altering body weight
Wang, F., Yoder, S. M., Yang, Q., Kohan, A. B., Kindel, T. L., Wang, J., & Tso, P. (2015) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00351.2013 · Cited by 30
Comprehensive analysis of the Co-structures of dipeptidyl peptidase IV and its inhibitor
Nojima, H., Kanou, K., Terashi, G., Takeda‐Shitaka, M., Inoue, G., Atsuda, K., Itoh, C., Iguchi, C., & Matsubara, H. (2016) · BMC Structural Biology · doi:10.1186/s12900-016-0062-8 · Cited by 30
The Effect of Exenatide on Thyroid-Stimulating Hormone and Thyroid Volume
Sencar, M. E., Sakız, D., Çalapkulu, M., Hepşen, S., Kızılgül, M., Ozturk, U. İ., Uçan, B., Bayram, M., Cagir, B. B., Akın, Ş., et al. (2019) · European Thyroid Journal · doi:10.1159/000501895 · Cited by 30
Ma, J., Rayner, C. K., Jones, K. L., & Horowitz, M. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.03.009 · Cited by 30
Rhee, N. A., Østoft, S. H., Holst, J. J., Deacon, C. F., Vilsbøll, T., & Knop, F. K. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0314 · Cited by 30
Self-citationParthsarathy, V., Irwin, N., Hasib, A., Martin, C. M., McClean, S., Bhat, V. K., Ng, M. T., Flatt, P. R., & Gault, V. A. (2016) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2016.01.015 · Cited by 30
Investigational treatments for Type 2 diabetes mellitus: exenatide and liraglutide
González, C. D., Beruto, V., Keller, G. A., Santoro, S., & Girolamo, G. D. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.8.887 · Cited by 30
Gene Expression of the Human Glucagon-Like Peptide-1 Receptor Is Regulated by Sp1 and Sp31
Wildhage, I., Trusheim, H., Göke, B., & Lankat–Buttgereit, B. (1999) · Endocrinology · doi:10.1210/endo.140.2.6512 · Cited by 30
Beyond Glycemic Control: Treating the Entire Type 2 Diabetes Disorder
Brunton, S. (2009) · Postgraduate Medicine · doi:10.3810/pgm.2009.09.2054 · Cited by 29
Cullinan, C. A., Brady, E. J., Saperstein, R., & Leibowitz, M. D. (1994) · Cell Calcium · doi:10.1016/0143-4160(94)90014-0 · Cited by 29
Hasib, A. (2020) · Clinical Medicine Insights: Endocrinology and Diabetes · doi:10.1177/1179551420905844 · Cited by 29
Rameshrad, M., Razavi, B. M., Ferns, G. A. A., & Hosseinzadeh, H. (2019) · DARU Journal of Pharmaceutical Sciences · doi:10.1007/s40199-019-00238-7 · Cited by 34
Immunomodulation and inflammation: Role of GLP-1R and GIPR expressing cells within the gut
Morrow, N. M., Morissette, A., & Mulvihill, E. E. (2024) · Peptides · doi:10.1016/j.peptides.2024.171200 · Cited by 32
Jiang, Y., Zhu, H., & Gong, F. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16106 · Cited by 35
Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes
Campbell, R. K., & Neumiller, J. J. (2010) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s7314 · Cited by 29
Gallwitz, B. (2013) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018813486165 · Cited by 20
Triplitt, C. L., Solis‐Herrera, C., Cersósimo, E., Abdul‐Ghani, M. A., & DeFronzo, R. A. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1114098 · Cited by 29
Hall, M. J., Adin, C. A., Borin‐Crivellenti, S., Rudinsky, A. J., Rajala‐Schultz, P. J., Lakritz, J., & Gilor, C. (2014) · Domestic Animal Endocrinology · doi:10.1016/j.domaniend.2014.12.001 · Cited by 30
Puddu, A., Mach, F., Nencioni, A., Viviani, G. L., & Montecucco, F. (2013) · Mediators of Inflammation · doi:10.1155/2013/591056 · Cited by 29
Luo, G.-C., Kong, X., Lü, L., Xu, X., Wang, H., & Ma, X. (2012) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2012.11.016 · Cited by 29
Watson, L. E., Phillips, L. K., Wu, T., Bound, M. J., Checklin, H. L., Grivell, J., Jones, K. L., Horowitz, M., & Rayner, C. K. (2018) · Clinical Nutrition · doi:10.1016/j.clnu.2018.12.014 · Cited by 29
Li, Y., Glotfelty, E. J., Namdar, I., Tweedie, D., Olson, L., Hoffer, B. J., DiMarchi, R. D., Pick, C. G., & Greig, N. H. (2019) · Experimental Neurology · doi:10.1016/j.expneurol.2019.113113 · Cited by 29
Uehara, S., Jung, S.-K., Morimoto, R., Arioka, S., Miyaji, T., Juge, N., Hiasa, M., Shimizu, K., Ishimura, A., Otsuka, M., et al. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03575.x · Cited by 29
Metadata
- Authors
- Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W.
- Affiliations
- University of Göttingen (DE)
- University of Copenhagen (DK)
- Rigshospitalet (DK)
- Venue
- Journal of Clinical Investigation
- Published
- 1993-01-01
- Volume
- 91
- Issue
- 1
- Pages
- 301-307
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC330027
- OpenAlex
- W1969932276
- Cited by
- 1,651
- References
- 41
- Citations by year
- 2026: 45 · 2025: 51 · 2024: 63 · 2023: 63 · 2022: 57 · 2021: 57 · 2020: 50 · 2019: 70 · 2018: 50 · 2017: 49 · 2016: 71 · 2015: 62 · 2014: 75 · 2013: 84 · 2012: 59
- FWCI
- 16.84
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- Deutsche Forschungsgemeinschaft (203/2-1)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- glucagon-like peptide-1, GLP-1(7-36)amide, glucose-dependent insulinotropic polypeptide, type 2 diabetes, insulin secretion, C-peptide, glucagon, hyperglycemic clamp, incretin resistance
- MeSH terms
- Insulin Secretion, Blood Glucose, C-Peptide, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Female, Gastric Inhibitory Polypeptide, Glucagon, Glycated Hemoglobin, Humans, Insulin, Kinetics, Male, Middle Aged, Peptide Fragments, Protein Precursors, Reference Values, Time Factors, Glucose Clamp Technique, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
